PARIS (Reuters) - French drugmaker Sanofi said its Sanofi Pasteur unit had signed a long-term cooperation deal with South Korea’s SK Chemical Co to develop and market a vaccine against pneumococcal infection.
Under the agreement, Sanofi will make an up-front payment of $23 million to SK Chemical Co, it said in a statement on Wednesday.
Both companies will co-invest in the development of the vaccine project and, if successful, SK Chemical will produce the vaccine at its production facility located in An-dong, in the southern part of Korea.
The product, once registered, will be launched globally by Sanofi Pasteur with shared profits outside of Korea, where SK would commercialize it with exclusive rights.
Reporting by Dominique Vidalon; Editing by Natalie Huet